| Date | Title | Description | Source |
| 01.04.2024 | Впервые в мире почку свиньи изменили генетически и пересадил... | Хирурги из США провели человеку трансплантацию почки, полученной из генетически модифицированной сви... | incrussia.... |
| 08.03.2024 | CRISPR Technology Takes Center Stage at SXSW 2024 for the Fi... | - | globenewsw... |
| 11.02.2022 | With sotrovimab in the balance, Biogen vet reunites with Geo... | Johanna Friedl-Naderer
Vir Biotechnology is getting another Biogen vet to join up as the startup’s n... | endpts.com... |
| 29.09.2021 | Editas Medicine : Review of BRILLIANCE Phase 1/2 Single Asce... | BRILLIANCE: A Phase 1/2 Single Ascending Dose Study of EDIT-101,
an in vivo CRISPR Gene Editing Ther... | marketscre... |
| 07.10.2020 | ‘A terrific choice’: George Church salutes fellow CRISPR pio... | George Church, who is in the thick of both the science and the business of editing genomes with the ... | statnews.c... |
| 16.10.2019 | Amarna raises €10M to push gene therapy platform into ... | → Amarna Therapeutics — developing an SV40-based gene delivery vector platform called SVa... | endpts.com... |
| 26.07.2019 | Editas, Allergan open first trial of in vivo CRISPR therapy | Last month, Chicago-based AbbVie said it would acquire Allergan – best known for manufacturing drugs... | medcitynew... |
| 22.01.2019 | Editas Medicine CEO steps down as company moves into product... | Editas’s stock fell more than 20 percent on the Nasdaq Tuesday morning following the announcement. T... | medcitynew... |
| 28.12.2018 | Andrew Hack to Join Bain Capital as a Managing Director | CAMBRIDGE, Mass., Dec. 21, 2018 (GLOBE NEWSWIRE) — Editas Medicine, Inc.(NASDAQ: EDIT), a leading ge... | citybizlis... |
| 17.07.2018 | New challenge filed to CRISPR patent licensed by Editas Medi... | Another key patent on the CRISPR genome editing technology is facing a legal challenge. On Tuesday, ... | statnews.c... |
| 15.02.2018 | With new CRISPR inventions, its pioneers say, you ain’t seen... | No one would be surprised if scientists announced tomorrow that CRISPR had leapt tall test tubes in ... | statnews.c... |
| 12.09.2017 | 23andMe raises $250M led by Sequoia Capital | Others in the genomics space that have raised funding include Counsyl, Veritas and Sophia
It's been ... | vator.tv/n... |
| 26.06.2017 | Who will pay for CRISPR? | The ruckus over the CRISPR gene-editing system hides a dark reality: its high cost may make it unaff... | statnews.c... |
| 25.04.2017 | The Broad Institute is testing the limits of what ‘nonprofit... | When a federal patent court ruled that the nonprofit Broad Institute of MIT and Harvard could legall... | statnews.c... |
| 03.03.2017 | Why does anybody own CRISPR? An argument against academic IP | Why does anybody own CRISPR?
His point: Intellectual property in academia is a drain on the system. ... | medcitynew... |
| 15.02.2017 | Editas breathes sigh of relief as CRISPR ruling handed down | This means that although the Broad patents were filed after the University of California’s, they are... | medcitynew... |
| 30.01.2017 | Is innovation a kind of intellectual immigration? | “The word pioneering for us is not an adjective, it’s not a compliment, it’s basically a verb,” said... | medcitynew... |
| 07.12.2016 | Kendall Square’s boarding school for biotechs | Mass Innovation Labs was late to the game, opening in May 2015. But it is clearly doing something di... | medcitynew... |
| 31.10.2016 | Third Rock Ventures closes $616 million healthcare fund | Fund IV has not yet begun investing, according to a company representative, but the firm has establi... | medcitynew... |
| 22.09.2016 | Monsanto licenses CRISPR technology to modify crops — with k... | Agriculture giant Monsanto has licensed CRISPR-Cas9 genome-editing technology from the Broad Institu... | statnews.c... |
| 22.08.2016 | Protocols: Editas recruits a Bristol-Myers vet as CSO... | Cambridge, MA-based gene editing stalwart Editas has recruited a Bristol-Myers vet for the ... | endpts.com... |
| 16.08.2016 | CRISPR patent fight: The legal bills are soaring | The meter is running like mad on the dispute over key patents on CRISPR genome editing. In its lates... | statnews.c... |
| 28.07.2016 | Protocols: Editas gets a gene editing collaborator;... | Gene editing pioneer Editas has signed on with the experts at the San Raffaele Telethon Inst... | endpts.com... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appeti... | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. B... | endpts.com... |
| 17.06.2016 | Philanthropist Bill Gates talks public health, biotech, and ... | Bill Gates became one of the richest men in history after cofounding Microsoft. His impact on the wo... | statnews.c... |
| 09.03.2016 | Editas biotech stock drops by 26 percent over CRISPR patent ... | Gene editing outfit Editas has been one of the most successful tech IPOs of 2016 so far, with shares... | techcrunch... |
| 25.01.2016 | CRISPR player Editas Medicine sets terms for $122M IPO | This is a relatively small fundraise, considering the fact that just five months ago it raised an im... | medcitynew... |
| 05.01.2016 | Advances in gene editing, and hype, underlie Editas move to ... | The public is only now hearing about the stunning potential of genome editing to treat diseases, and... | statnews.c... |
| 05.01.2016 | These infographics outline Editas’ post-IPO strategy | Here’s an interesting infographic from the prospectus that outlines Editas’ plans for expansion, in ... | medcitynew... |
| 04.01.2016 | Biotech Startups Hit the Ground Running, With Six Filing IPO... | If we had to gamble on it, we’d bet the IPO market will be far more brisk this year than last year, ... | techcrunch... |
| 07.12.2015 | Google Ventures CEO: Our focus on the life sciences will gro... | That said, Google Ventures, newly christened “GV” per its new website, will reduce its investments i... | medcitynew... |
| 06.11.2015 | Watch: Meet one of the world’s most groundbreaking scientist... | As the dish of steamed chicken feet clattered onto the table, an impish toddler drummed with her cho... | statnews.c... |
| 11.08.2015 | CRISPR: Editas’ $120M proves it isn’t a bunch of hype. Here ... | But that’s already turned quickly on its head.
Confidence is growing in the technology, as evidenced... | medcitynew... |
| 10.08.2015 | Gene-editing startup Editas just raised $120m from Bill Gate... | | cityam.com... |
| 10.08.2015 | Editas Medicine Raises $120M in Series B |
CAMBRIDGE, MA, Leading genome editing company, today announced that it has raised $120 million in ... | vcnewsdail... |
| 10.08.2015 | Editas Medicine Raises $120M in Series B Financing (Update) | Editas Medicine, a Cambridge, MA-based genome editing company, raised $120m in Series B private fina... | finsmes.co... |
| 10.08.2015 | Genome editing company Editas gets infused with $120M | Investors in the company include Google Ventures, Khosla Ventures and Bill Gates
We like to complain... | vator.tv/n... |
| 10.08.2015 | Gates backs a $120M breakout round for CRISPR/Cas9 pioneers ... | Editas CEO Katrine Bosley
Editas quickly emerged as one of the first biotech upstarts with potential... | fiercebiot... |
| 10.08.2015 | Editas Medicine Raises $20M in Venture Capital Funding | Editas Medicine, a Cambridge, MA-based developer of genome-editing technology, raised $20m in ventur... | finsmes.co... |
| 10.08.2015 | Daily funding roundup - August 10, 2015 | Editas Medicine Inc secured $120M; Turing Pharmaceuticals bagged $90M; Vainglory raised $26M
Editas ... | vator.tv/n... |
| 23.06.2015 | Five conspicuous omissions from MIT Tech Review’s 50 smartes... | …we did not have trouble finding big ideas. To make the list, a company must have truly innovative t... | medcitynew... |
| 13.05.2015 | The Genome Engineering Revolution | Ryan Clarke Contributor
More posts by this contributor
A Third Act For Biofuels
James Hyun Contribut... | techcrunch... |
| 26.11.2013 | Editas Medicine Launches with $43M in Series A |
CAMBRIDGE, MA, Transformative genome editing company, today announced it has secured a $43 million... | vcnewsdail... |
| 25.11.2013 | Editas Medicine Secures $43M Series A Financing | Editas Medicine, a Cambridge, MA-based genome editing company, secured a $43m Series A financing.
Th... | finsmes.co... |
| - | After falling behind gene-editing rivals, Editas just got a ... | Editas Medicine CEO James Mullen Editas Medicine This story is available exclusively to Insider subs... | businessin... |
| - | Is innovation a kind of intellectual immigration? | With over 75 scientific ventures to its name, Flagship’s startup network has now generated 16 IPOs a... | medcitynew... |
| - | CRISPR: Editas’ $120M proves it isn’t a bunch of hype. Here ... | CRISPR/Cas9 gene editing has zoomed to the forefront of the biotech investment scape in the past yea... | medcitynew... |
| - | Editas Medicine CEO steps down as company moves into product... | Shares of companies across the emerging field of gene editing fell Tuesday morning as one of the mor... | medcitynew... |
| - | Editas Medicine raises $94.4 million in year’s first IPO | - | bostonglob... |
| - | Google Ventures CEO: Our focus on the life sciences will gro... | Nearly a third of Google Ventures‘ investments are in the life sciences, according to the firm’s pre... | medcitynew... |
| - | Kendall Square’s boarding school for biotechs | A communal area at the Mass Innovation Labs facility
It’s hard to get excited about a biotech shared... | medcitynew... |
| - | CRISPR player Editas Medicine sets terms for $122M IPO | CRISPR gene editing player Editas Medicine just set the terms for its forthcoming IPO, according to ... | medcitynew... |
| - | Five conspicuous omissions from MIT Tech Review’s 50 smartes... | We know who made the cut in the latest MIT Technology Review list of the 50 Smartest Companies of 20... | medcitynew... |
| - | These infographics outline Editas’ post-IPO strategy | Cambridge gene editing startup Editas Medicine just filed for a $100 million IPO, marking it the fir... | medcitynew... |
| - | Why does anybody own CRISPR? An argument against academic IP | Who owns CRISPR?
It has – and continues to be – one of the biggest intellectual property debates in ... | medcitynew... |
| - | Editas breathes sigh of relief as CRISPR ruling handed down | A day after experts weighed in on the ethical concerns of CRISPR, the U.S. Patent Trial and Appeal B... | medcitynew... |
| - | Third Rock Ventures closes $616 million healthcare fund | Third Rock Ventures announced Monday that it had closed its fourth fund — it’s largest, Third Rock V... | medcitynew... |
| - | Editas, Allergan open first trial of in vivo CRISPR therapy | A clinical trial of a CRISPR/Cas9-based gene therapy in an inherited form of blindness is expected t... | medcitynew... |
